Eph receptors and ephrins in cancer: bidirectional signalling and beyond

The Eph receptor tyrosine kinases and their ephrin ligands have intriguing expression patterns in cancer cells and tumour blood vessels, which suggest important roles for their bidirectional signals in many aspects of cancer development and progression. Eph gene mutations probably also contribute to cancer pathogenesis. Eph receptors and ephrins have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumour growth, invasiveness, angiogenesis and metastasis in vivo. However, Eph signalling activities in cancer seem to be complex, and are characterized by puzzling dichotomies. Nevertheless, the Eph receptors are promising new therapeutic targets in cancer.

[1]  P. Dobrzanski,et al.  Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist , 2004, Cancer Research.

[2]  M. Hendrix,et al.  VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: Implications for vasculogenic mimicry , 2006, Cancer biology & therapy.

[3]  A. Boyd,et al.  Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. , 1999, Blood.

[4]  E. Pasquale,et al.  Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor. , 2009, The Biochemical journal.

[5]  Fei Huang,et al.  Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.

[6]  H. Augustin,et al.  Involvement of endothelial ephrin-B2 in adhesion and transmigration of EphB-receptor-expressing monocytes , 2008, Journal of Cell Science.

[7]  M. Berens,et al.  The phosphorylation of ephrin‐B2 ligand promotes glioma cell migration and invasion , 2009, International journal of cancer.

[8]  Jimmy Lin,et al.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.

[9]  Dana M. Brantley-Sieders,et al.  Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. , 2009, Molecular biology of the cell.

[10]  L. Tessarollo,et al.  ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3 , 2007, Proceedings of the National Academy of Sciences.

[11]  A. Reith,et al.  Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. , 2003, Neoplasia.

[12]  T. Langmann,et al.  Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. , 2004, Clinical chemistry.

[13]  Hiroyuki Yamamoto,et al.  Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. , 2007, Carcinogenesis.

[14]  A. Andres,et al.  Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. , 1998, Journal of cell science.

[15]  Dana M. Brantley-Sieders,et al.  Essential Role of Vav Family Guanine Nucleotide Exchange Factors in EphA Receptor-Mediated Angiogenesis , 2006, Molecular and Cellular Biology.

[16]  Jin Man Kim,et al.  Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2–q29 in squamous cell carcinoma of the lung , 2009, BMC Cancer.

[17]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[18]  S. Bolsover,et al.  Regeneration‐enhancing effects of EphA4 blocking peptide following corticospinal tract injury in adult rat spinal cord , 2007, The European journal of neuroscience.

[19]  S. Orsulic,et al.  Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. , 2000, Journal of cell science.

[20]  W. Cai,et al.  Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  C. Moens,et al.  EphA4 and EfnB2a maintain rhombomere coherence by independently regulating intercalation of progenitor cells in the zebrafish neural keel. , 2009, Developmental biology.

[22]  J. West,et al.  EphrinAl-targeted nanoshells for photothermal ablation of prostate cancer cells , 2008, International journal of nanomedicine.

[23]  Jean Y. J. Wang,et al.  Induction of cell retraction by the combined actions of Abl–CrkII and Rho–ROCK1 signaling , 2008, The Journal of cell biology.

[24]  R. Willemze,et al.  Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression Analysis , 2004, Cancer Research.

[25]  Ravi Salgia,et al.  The role of ephrins and Eph receptors in cancer. , 2004, Cytokine & growth factor reviews.

[26]  R. Abagyan,et al.  Three-dimensional Structure of the EphB2 Receptor in Complex with an Antagonistic Peptide Reveals a Novel Mode of Inhibition* , 2007, Journal of Biological Chemistry.

[27]  Y. Oda,et al.  Synaptic activity prompts γ-secretase–mediated cleavage of EphA4 and dendritic spine formation , 2009, The Journal of cell biology.

[28]  A. Pandey,et al.  Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. , 1995, Science.

[29]  J A Biegel,et al.  Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein-tyrosine kinase gene of the EPH family. , 1995, Human molecular genetics.

[30]  T. Pawson,et al.  EphB receptor activity suppresses colorectal cancer progression , 2005, Nature.

[31]  H. Hirai,et al.  Overexpression confers an oncogenic potential upon the eph gene. , 1990, Oncogene.

[32]  J. Frisén,et al.  Meltrin β/ADAM19 Interacting with EphA4 in Developing Neural Cells Participates in Formation of the Neuromuscular Junction , 2008, PloS one.

[33]  Jimmy Peng,et al.  A role for C. elegans Eph RTK signaling in PTEN regulation. , 2009, Developmental cell.

[34]  D. Maric,et al.  EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. , 2009, Blood.

[35]  J. Finke,et al.  Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists1 , 2008, The Journal of Immunology.

[36]  A. Pozzi,et al.  Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo , 2002, Oncogene.

[37]  H. Sugimura,et al.  Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. , 2007, Human pathology.

[38]  T. Iwasato,et al.  β2‐Chimaerin binds to EphA receptors and regulates cell migration , 2009, FEBS letters.

[39]  Jennifer L. Cutter,et al.  EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. , 2009, Cancer cell.

[40]  R. Neve,et al.  A conditional feedback loop regulates Ras activity through EphA2. , 2005, Cancer cell.

[41]  S. Goff,et al.  Dissociation of EphB2 Signaling Pathways Mediating Progenitor Cell Proliferation and Tumor Suppression , 2009, Cell.

[42]  P. Kuhn,et al.  Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. , 2006, Structure.

[43]  T. Spector,et al.  EPHA2 Is Associated with Age-Related Cortical Cataract in Mice and Humans , 2009, PLoS genetics.

[44]  H. Matsuoka,et al.  Biphasic Functions of the Kinase-defective Ephb6 Receptor in Cell Adhesion and Migration* , 2005, Journal of Biological Chemistry.

[45]  J. Schlessinger,et al.  Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. McDonald,et al.  Capillary defects and exaggerated inflammatory response in the airways of EphA2-deficient mice. , 2009, The American journal of pathology.

[47]  Elena B Pasquale,et al.  EphB Receptor-binding Peptides Identified by Phage Display Enable Design of an Antagonist with Ephrin-like Affinity* , 2005, Journal of Biological Chemistry.

[48]  W. Xia,et al.  Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. , 2006, Neoplasia.

[49]  T. Shuin,et al.  Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. , 2002, Cancer genetics and cytogenetics.

[50]  P. Brandt-Rauf,et al.  A Novel Mechanism for p53 to Regulate Its Target Gene ECK in Signaling Apoptosis , 2006, Molecular Cancer Research.

[51]  J. D. Stuart,et al.  Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases. , 2007, Bioorganic & medicinal chemistry letters.

[52]  D. Arvanitis,et al.  Eph/ephrin signaling: networks. , 2008, Genes & development.

[53]  J. Biegel,et al.  ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. , 1997, Genomics.

[54]  J. Stein,et al.  EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival , 2006, Oncogene.

[55]  D. McCance,et al.  Constitutive activation of the Raf–MAPK pathway causes negative feedback inhibition of Ras–PI3K–AKT and cellular arrest through the EphA2 receptor , 2008, Oncogene.

[56]  S. Fröhling,et al.  Chromosomal abnormalities in cancer. , 2008, The New England journal of medicine.

[57]  Jarnail Singh,et al.  Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. , 2006, Cancer research.

[58]  A. Sood,et al.  EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. , 2009, Journal of the National Cancer Institute.

[59]  Andrew J. Wilson,et al.  The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. , 2009, Cancer research.

[60]  Dana M. Brantley-Sieders,et al.  The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. , 2008, The Journal of clinical investigation.

[61]  G. Serban,et al.  Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB‐induced Src phosphorylation and signaling , 2006, The EMBO journal.

[62]  M. Kanamori,et al.  Downregulation of EphA7 by hypermethylation in colorectal cancer , 2005, Oncogene.

[63]  E. Todeva.  Networks , 2007 .

[64]  T. Itakura,et al.  EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line , 2008, Molecular Cancer Therapeutics.

[65]  Andrew D. Yates,et al.  Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.

[66]  Santhosh K. P. Kumar,et al.  Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. , 2006, The American journal of pathology.

[67]  Tony Pawson,et al.  β-Catenin and TCF Mediate Cell Positioning in the Intestinal Epithelium by Controlling the Expression of EphB/EphrinB , 2002, Cell.

[68]  Nathanael S Gray,et al.  Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[69]  Jan Huisken,et al.  Arterial-Venous Segregation by Selective Cell Sprouting: An Alternative Mode of Blood Vessel Formation , 2009, Science.

[70]  Liz Y. Han,et al.  Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. , 2006, Journal of the National Cancer Institute.

[71]  E. Dickerson,et al.  Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[72]  Cu Nguyen,et al.  Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. , 2009, Cancer research.

[73]  A. Scott,et al.  Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. , 2005, Cancer research.

[74]  湯本 法弘.  Meltrin β/ADAM19 interacting with EphA4 in developing neural cells participates in formation of the neuromuscular junction , 2008 .

[75]  John F. McDonald,et al.  Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. , 2008, Journal of the American Chemical Society.

[76]  M. Kinch,et al.  Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1 , 2004, Cancer Gene Therapy.

[77]  Tony Pawson,et al.  Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer , 2004, Nature Genetics.

[78]  Q. Lu,et al.  ZHX2 Interacts with Ephrin-B and Regulates Neural Progenitor Maintenance in the Developing Cerebral Cortex , 2009, The Journal of Neuroscience.

[79]  S. Brenner,et al.  Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. , 2007, Cancer research.

[80]  Tagvor G. Nishanian,et al.  EphrinB1 controls cell–cell junctions through the Par polarity complex , 2008, Nature Cell Biology.

[81]  M. Simons,et al.  Modern Concepts in Angiogenesis , 2007 .

[82]  Jin Chen,et al.  Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism , 2008, Journal of Cell Science.

[83]  Alexander I. Son,et al.  Loss of ephrin-A5 function disrupts lens fiber cell packing and leads to cataract , 2008, Proceedings of the National Academy of Sciences.

[84]  Herren Wu,et al.  Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. , 2009, Neoplasia.

[85]  Anthony W. Zoghbi,et al.  The Amyotrophic Lateral Sclerosis 8 Protein VAPB Is Cleaved, Secreted, and Acts as a Ligand for Eph Receptors , 2008, Cell.

[86]  M. Kinch,et al.  E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[87]  H. Shepard,et al.  Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis , 2008, Arthritis research & therapy.

[88]  J. Isaacs,et al.  Hsp90 Is an Essential Regulator of EphA2 Receptor Stability and Signaling: Implications for Cancer Cell Migration and Metastasis , 2009, Molecular Cancer Research.

[89]  Spencer C. Alford,et al.  Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. , 2007, Experimental cell research.

[90]  Kai Lin,et al.  Ephrin-B2-induced Cleavage of EphB2 Receptor Is Mediated by Matrix Metalloproteinases to Trigger Cell Repulsion* , 2008, Journal of Biological Chemistry.

[91]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[92]  D. Xie,et al.  EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor , 2009, Oncogene.

[93]  Jan Tavernier,et al.  MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells. , 2006, Chemistry & biology.

[94]  B. Leggett,et al.  Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival , 2009, British Journal of Cancer.

[95]  H. Hirai,et al.  A novel putative tyrosine kinase receptor encoded by the eph gene. , 1987, Science.

[96]  Andrew I Su,et al.  An efficient rapid system for profiling the cellular activities of molecular libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[97]  R. Adams,et al.  Ephrin-B2 Controls Cell Motility and Adhesion during Blood-Vessel-Wall Assembly , 2006, Cell.

[98]  J. Finke,et al.  Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. , 2003, Cancer research.

[99]  Y. Maru,et al.  EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility , 2009, Journal of Cell Science.

[100]  K. Baggerly,et al.  Dual targeting of EphA2 and FAK in ovarian carcinoma , 2009, Cancer biology & therapy.

[101]  Elena B. Pasquale,et al.  The Eph family: a multitude of receptors that mediate cell recognition signals , 1997, Cell and Tissue Research.

[102]  Eugene S. Kim,et al.  Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. , 2004, Molecular cancer research : MCR.

[103]  A. Georgakopoulos,et al.  Ligand Binding and Calcium Influx Induce Distinct Ectodomain/γ-Secretase-processing Pathways of EphB2 Receptor* , 2007, Journal of Biological Chemistry.

[104]  Jin Chen,et al.  EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. , 2005, Current cancer drug targets.

[105]  M. Deavers,et al.  The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome , 2007, British Journal of Cancer.

[106]  R. Sakai,et al.  Phosphorylation of ephrin‐B1 via the interaction with claudin following cell–cell contact formation , 2005, The EMBO journal.

[107]  Elena B Pasquale,et al.  Eph-Ephrin Bidirectional Signaling in Physiology and Disease , 2008, Cell.

[108]  Bao-cun Sun,et al.  Functional significance of VEGF-a in human ovarian carcinoma: Role in vasculogenic mimicry , 2008, Cancer biology & therapy.

[109]  L. Cantley,et al.  EphA kinase activation regulates HGF-induced epithelial branching morphogenesis , 2003, The Journal of cell biology.

[110]  Andrew J. Wilson,et al.  Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. , 2005, Cancer research.

[111]  E. Pasquale,et al.  The EphB4 Receptor-tyrosine Kinase Promotes the Migration of Melanoma Cells through Rho-mediated Actin Cytoskeleton Reorganization* , 2006, Journal of Biological Chemistry.

[112]  D. Arango,et al.  EPH receptors in cancer. , 2008, Histology and histopathology.

[113]  T. Hudson,et al.  Germline EPHB2 Receptor Variants in Familial Colorectal Cancer , 2008, PloS one.

[114]  Elena B Pasquale,et al.  An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor* , 2002, The Journal of Biological Chemistry.

[115]  M. Henkemeyer,et al.  Ephrin-B3 reverse signaling through Grb4 and cytoskeletal regulators mediates axon pruning , 2009, Nature Neuroscience.

[116]  B. Tycko,et al.  Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation , 2002, Molecular Cancer.

[117]  Jingjing Sun,et al.  EphA4 as an effector of Twist1 in the guidance of osteogenic precursor cells during calvarial bone growth and in craniosynostosis , 2009, Development.

[118]  S. Langermann,et al.  Differential EphA2 epitope display on normal versus malignant cells. , 2003, Cancer research.

[119]  Stephen W. Wilson,et al.  Eph/Ephrin Signaling Regulates the Mesenchymal-to-Epithelial Transition of the Paraxial Mesoderm during Somite Morphogenesis , 2003, Current Biology.

[120]  H. Augustin,et al.  Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment. , 2008, Blood.

[121]  E. Pasquale,et al.  Multiple in vivo tyrosine phosphorylation sites in EphB receptors. , 1999, Biochemistry.

[122]  H. Miao,et al.  Eph/ephrin signaling in epithelial development and homeostasis. , 2009, The international journal of biochemistry & cell biology.

[123]  F. Lemonnier,et al.  EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. , 2003, Cancer research.

[124]  G. Roth,et al.  Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors* , 2008, Journal of Biological Chemistry.

[125]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[126]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[127]  M. Landthaler,et al.  Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. , 2005, International journal of oncology.

[128]  S. Ashley,et al.  EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma , 2004, Oncogene.

[129]  J. Lloreta,et al.  EphB–ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells , 2007, Nature Genetics.

[130]  Chen-Yang Shen,et al.  High‐resolution 19p13.2–13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity , 2004, Genes, chromosomes & cancer.

[131]  M. Kinch,et al.  Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. , 2002, Cancer research.

[132]  M. Honda,et al.  Ephrin-A1 expression contributes to the malignant characteristics of α-fetoprotein producing hepatocellular carcinoma , 2005, Gut.

[133]  Peter Vajkoczy,et al.  EphB4 controls blood vascular morphogenesis during postnatal angiogenesis , 2006, The EMBO journal.

[134]  Jon Read,et al.  Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. , 2008, Bioorganic & medicinal chemistry letters.

[135]  Dana M. Brantley-Sieders,et al.  Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. , 2006, Cancer research.

[136]  Paul Polakis,et al.  EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer , 2004, Cancer Research.

[137]  Tony Pawson,et al.  Cell-Specific Information Processing in Segregating Populations of Eph Receptor Ephrin–Expressing Cells , 2009, Science.

[138]  W. Debinski,et al.  Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor , 2008, Oncogene.

[139]  N. Ip,et al.  Identification of the Jak/Stat Proteins as Novel Downstream Targets of EphA4 Signaling in Muscle , 2004, Journal of Biological Chemistry.

[140]  E. Pasquale,et al.  Paradoxes of the EphB4 receptor in cancer. , 2007, Cancer research.

[141]  M. Kinch,et al.  Regulation of the EphA2 Kinase by the Low Molecular Weight Tyrosine Phosphatase Induces Transformation* , 2002, The Journal of Biological Chemistry.

[142]  U. Sinha,et al.  The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. , 2006, Archives of otolaryngology--head & neck surgery.

[143]  K. Murai,et al.  Targeting the EphA4 receptor in the nervous system with biologically active peptides , 2003, Molecular and Cellular Neuroscience.

[144]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[145]  S. Attwell,et al.  Ephrin A5 expression promotes invasion and transformation of murine fibroblasts. , 2006, Biochemical and biophysical research communications.

[146]  N. Hayashi,et al.  Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2‐derived peptide‐pulsed dendritic cell vaccines , 2007, Cancer.

[147]  David G. Wilkinson,et al.  Regulation of EphB2 activation and cell repulsion by feedback control of the MAPK pathway , 2008, The Journal of cell biology.

[148]  J. Guan,et al.  Inhibition of Integrin-mediated Cell Adhesion but Not Directional Cell Migration Requires Catalytic Activity of EphB3 Receptor Tyrosine Kinase , 2005, Journal of Biological Chemistry.

[149]  Mitsutoshi Nakada,et al.  EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. , 2005, The American journal of pathology.

[150]  K. Kinzler,et al.  Identification and classification of p53-regulated genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[151]  R. Noberini,et al.  Crystal Structure and NMR Binding Reveal That Two Small Molecule Antagonists Target the High Affinity Ephrin-binding Channel of the EphA4 Receptor* , 2008, Journal of Biological Chemistry.

[152]  E. Pasquale,et al.  Eph receptors inactivate R-Ras through different mechanisms to achieve cell repulsion , 2006, Journal of Cell Science.

[153]  W. Debinski,et al.  A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor–expressing tumor cells , 2007, Molecular Cancer Therapeutics.

[154]  T. Pawson,et al.  Cell Signaling in Space and Time: Where Proteins Come Together and When They’re Apart , 2009, Science.

[155]  Rüdiger Klein,et al.  Bidirectional modulation of synaptic functions by Eph/ephrin signaling , 2009, Nature Neuroscience.

[156]  Cédric Leroy,et al.  Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. , 2009, Cancer research.

[157]  Elena B. Pasquale,et al.  Developmental cell biology: Eph receptor signalling casts a wide net on cell behaviour , 2005, Nature Reviews Molecular Cell Biology.

[158]  L. Neckers,et al.  Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. , 2009, Cancer research.

[159]  M. Guan,et al.  Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features , 2009, International journal of cancer.

[160]  M. Mansukhani,et al.  Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression , 2003, Oncogene.

[161]  H. Sakuta,et al.  Eph receptors are negatively controlled by protein tyrosine phosphatase receptor type O , 2006, Nature Neuroscience.

[162]  Andrew J. Wilson,et al.  EPHB4 and survival of colorectal cancer patients. , 2006, Cancer research.

[163]  R. Sakai,et al.  The C-terminus of ephrin-B1 regulates metalloproteinase secretion and invasion of cancer cells , 2007, Journal of Cell Science.

[164]  King-Jen Chang,et al.  Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. , 2009, Carcinogenesis.

[165]  P. Li,et al.  c‐Rel is a transcriptional repressor of EPHB2 in colorectal cancer , 2009, The Journal of pathology.

[166]  Santhosh K. P. Kumar,et al.  The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. , 2006, Blood.

[167]  A. Boyd,et al.  Ephrin expression and function in cancer. , 2010, Future oncology.

[168]  Q. Qian,et al.  Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases , 2009, Expert opinion on therapeutic patents.

[169]  D. Arango,et al.  High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability , 2007, Oncogene.

[170]  A. Caflisch,et al.  Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). , 2009, Journal of medicinal chemistry.

[171]  J G Flanagan,et al.  Regulated cleavage of a contact-mediated axon repellent. , 2000, Science.

[172]  W. Debinski,et al.  The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting , 2008, Molecular Cancer Research.

[173]  Damon L. Meyer,et al.  A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. , 2008, Cancer research.

[174]  Y. Fujii‐Kuriyama,et al.  Hypoxia-inducible Transcription Factor-2α in Endothelial Cells Regulates Tumor Neovascularization through Activation of Ephrin A1* , 2008, Journal of Biological Chemistry.

[175]  J. Nikawa,et al.  Erythropoietin‐producing hepatocyte B6 variant‐derived peptides with the ability to induce glioma‐reactive cytotoxic T lymphocytes in human leukocyte antigen‐A2+ glioma patients , 2008, Cancer science.

[176]  E. Nievergall,et al.  Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. , 2008, Blood.

[177]  N. Mochizuki,et al.  EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts. , 2009, Molecular biology of the cell.

[178]  E. Pasquale,et al.  Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. , 2004, Cellular signalling.

[179]  P. Chiarugi,et al.  EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. , 2009, Cancer research.

[180]  F. Yakes,et al.  Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647 , 2007, Clinical Cancer Research.

[181]  R. Sakai,et al.  Phosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinoma. , 2007, The American journal of pathology.

[182]  M. Bienz.  Faculty Opinions recommendation of Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. , 2002 .

[183]  Jon Read,et al.  Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines. , 2008, Bioorganic & medicinal chemistry letters.

[184]  Martin Vingron,et al.  Comparative 3'UTR Analysis Allows Identification of Regulatory Clusters that Drive Eph/ephrin Expression in Cancer Cell Lines , 2008, PloS one.

[185]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[186]  M. Berens,et al.  Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. , 2006, Cancer research.

[187]  Fabio Martelli,et al.  MicroRNA-210 Modulates Endothelial Cell Response to Hypoxia and Inhibits the Receptor Tyrosine Kinase Ligand Ephrin-A3* , 2008, Journal of Biological Chemistry.

[188]  B. Lévy,et al.  PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells. , 2007, The Journal of clinical investigation.

[189]  R. Geyer,et al.  In Human Leukemia Cells Ephrin-B–Induced Invasive Activity Is Supported by Lck and Is Associated with Reassembling of Lipid Raft Signaling Complexes , 2008, Molecular Cancer Research.

[190]  Michael Thomas,et al.  Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. , 2005, Cancer research.

[191]  A. Caflisch,et al.  Structure‐based tailoring of compound libraries for high‐throughput screening: Discovery of novel EphB4 kinase inhibitors , 2008, Proteins.

[192]  T. Pawson,et al.  Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer , 2008, British Journal of Cancer.

[193]  P. Kufer,et al.  Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. , 2007, Cancer research.

[194]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[195]  Jin Chen,et al.  Regulation of EphA2 Receptor Endocytosis by SHIP2 Lipid Phosphatase via Phosphatidylinositol 3-Kinase-dependent Rac1 Activation* , 2007, Journal of Biological Chemistry.

[196]  A. Sood,et al.  EphA2 as a target for ovarian cancer therapy , 2005, Expert opinion on therapeutic targets.

[197]  M. Shekhar,et al.  Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. , 2001, Cancer research.

[198]  Dana M. Brantley-Sieders,et al.  A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis , 2005, Oncogene.

[199]  Lu Xie,et al.  Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. , 2010, Cancer research.

[200]  H. Augustin,et al.  Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. , 2006, Experimental cell research.

[201]  L. Aaltonen,et al.  Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis , 2007, Oncogene.

[202]  R. Raychowdhury,et al.  Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. , 2009, Cancer research.

[203]  M. Kinch,et al.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells. , 2001, Cancer research.

[204]  Ke Chen,et al.  Dissecting the EphA3/Ephrin-A5 Interactions Using a Novel Functional Mutagenesis Screen* , 2004, Journal of Biological Chemistry.

[205]  Yue-zhong Wu,et al.  Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas , 2007, Oncogene.

[206]  Mustafa Sahin,et al.  Tsc2-Rheb Signaling Regulates EphA-Mediated Axon Guidance , 2009, Nature Neuroscience.

[207]  Santhosh K. P. Kumar,et al.  The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. , 2009, Blood.

[208]  P. Bosma,et al.  Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. , 2009, World journal of gastroenterology.

[209]  M. Turunen,et al.  Hypoxia induces microRNA miR‐210 in vitro and in vivo , 2008, FEBS letters.

[210]  C. Gu,et al.  The EphA8 Receptor Regulates Integrin Activity through p110γ Phosphatidylinositol-3 Kinase in a Tyrosine Kinase Activity-Independent Manner , 2001, Molecular and Cellular Biology.

[211]  H. Augustin,et al.  Inhibition of tumor growth and angiogenesis by soluble EphB4. , 2004, Neoplasia.

[212]  Shinichiro Kumagaya,et al.  Fluid shear stress induces arterial differentiation of endothelial progenitor cells. , 2009, Journal of applied physiology.

[213]  B. Deurs,et al.  Activation of the EGFR Gene Target EphA2 Inhibits Epidermal Growth Factor–Induced Cancer Cell Motility , 2007, Molecular Cancer Research.

[214]  E. Pasquale,et al.  Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[215]  J. Pinski,et al.  EphB4 expression and biological significance in prostate cancer. , 2005, Cancer research.

[216]  P. Mehlen,et al.  EphrinB3 is an anti-apoptotic ligand that inhibits the dependence receptor functions of EphA4 receptors during adult neurogenesis. , 2009, Biochimica et biophysica acta.

[217]  K. Seyb,et al.  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[218]  G. Yancopoulos,et al.  Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. , 2002, Molecular cancer research : MCR.

[219]  R. Kandpal,et al.  Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR. , 2006, Biochemical and biophysical research communications.

[220]  E. Pasquale,et al.  The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization , 2000, Oncogene.

[221]  Elena B. Pasquale,et al.  The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl–Crk pathway , 2006, Nature Cell Biology.

[222]  P. Coulie,et al.  Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. , 2000, Cancer research.

[223]  Michael Dohn,et al.  Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis , 2001, Oncogene.

[224]  S. Tsugane,et al.  Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer. , 2001, Cancer letters.

[225]  Yosef Yarden,et al.  B61 is a ligand for the ECK receptor protein-tyrosine kinase , 1994, Nature.

[226]  Michael Landthaler,et al.  Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer , 2006, Modern Pathology.

[227]  T. Carpenter,et al.  Endothelial EphA receptor stimulation increases lung vascular permeability. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[228]  D. O'Leary,et al.  p75NTR Mediates Ephrin-A Reverse Signaling Required for Axon Repulsion and Mapping , 2008, Neuron.

[229]  Sanne Kuijper,et al.  Regulation of angiogenesis by Eph-ephrin interactions. , 2007, Trends in cardiovascular medicine.

[230]  J. Rhim,et al.  Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway , 2001, Nature Cell Biology.

[231]  I. Pollack,et al.  EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. , 2005, Neoplasia.